Baxter International Company Profile (NYSE:BAX)

About Baxter International (NYSE:BAX)

Baxter International logoBaxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:BAX
  • CUSIP: 07181310
  • Web: www.baxter.com
Capitalization:
  • Market Cap: $34.94 billion
  • Outstanding Shares: 544,870,000
Average Prices:
  • 50 Day Moving Avg: $63.14
  • 200 Day Moving Avg: $59.72
  • 52 Week Range: $43.13 - $64.75
P/E:
  • Trailing P/E Ratio: 38.91
  • Foreward P/E Ratio: 24.01
  • P/E Growth: 2.00
Sales & Book Value:
  • Annual Revenue: $10.28 billion
  • Price / Sales: 3.40
  • Book Value: $16.85 per share
  • Price / Book: 3.81
Dividend:
  • Annual Dividend: $0.64
  • Dividend Yield: 1.0%
Profitability:
  • EBITDA: $2.23 billion
  • Net Margins: 8.85%
  • Return on Equity: 14.82%
  • Return on Assets: 8.06%
Debt:
  • Debt-to-Equity Ratio: 0.38%
  • Current Ratio: 3.01%
  • Quick Ratio: 2.42%
Misc:
  • Average Volume: 2.26 million shs.
  • Beta: 0.65
  • Short Ratio: 2.48
 

Frequently Asked Questions for Baxter International (NYSE:BAX)

What is Baxter International's stock symbol?

Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."

How often does Baxter International pay dividends? What is the dividend yield for Baxter International?

Baxter International declared a quarterly dividend on Tuesday, July 18th. Investors of record on Friday, September 1st will be paid a dividend of $0.16 per share on Monday, October 2nd. This represents a $0.64 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date is Wednesday, August 30th. View Baxter International's Dividend History.

How were Baxter International's earnings last quarter?

Baxter International Inc. (NYSE:BAX) issued its quarterly earnings data on Wednesday, July, 26th. The company reported $0.63 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.57 by $0.06. The firm had revenue of $2.61 billion for the quarter, compared to analysts' expectations of $2.59 billion. Baxter International had a return on equity of 14.82% and a net margin of 8.85%. The company's revenue was up .8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.46 earnings per share. View Baxter International's Earnings History.

When will Baxter International make its next earnings announcement?

Baxter International is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Baxter International.

What guidance has Baxter International issued on next quarter's earnings?

Baxter International updated its FY17 earnings guidance on Wednesday, July, 26th. The company provided earnings per share (EPS) guidance of $2.34-2.40 for the period, compared to the Thomson Reuters consensus estimate of $2.27. The company issued revenue guidance of $10.67 billion, compared to the consensus revenue estimate of $10.37 billion.Baxter International also updated its Q3 guidance to $0.58-0.60 EPS.

Where is Baxter International's stock going? Where will Baxter International's stock price be in 2017?

11 equities research analysts have issued twelve-month target prices for Baxter International's stock. Their forecasts range from $55.00 to $75.00. On average, they expect Baxter International's share price to reach $65.73 in the next year. View Analyst Ratings for Baxter International.

What are analysts saying about Baxter International stock?

Here are some recent quotes from research analysts about Baxter International stock:

  • 1. According to Zacks Investment Research, "Over the past year, Baxter has outperformed the broader industry in terms of price performance. The company rides on the recent launch of DeviceVue, a comprehensive asset tracking solution available exclusively to hospitals. However, lower cyclophosphamide sales in the coming quarters might mar the Baxter’s bottom line. Of the major positives, a favorable product mix, stringent cost control and expanding operating margin are notable. Baxter reported impressive results in the second quarter, driven by favorable tidings on the regulatory front, strategic partnerships and product launches. The company recently completed the acquisition of Claris Injectables. Solid U.S. sales of IV therapies, IV access sets, select anesthesia and critical care products are key catalysts at the moment. On the flipside, a strong U.S. dollar, intensifying competition and lackluster sales growth are key concerns at the moment." (10/16/2017)
  • 2. UBS AG analysts commented, "Management delivered a solid 7c beat to our EPS estimate (+5c to consensus) driven by Fluid Systems (+$32 mil) and roughly in-line revenues across other major business lines. On the earnings line, higher sales net of COGS (+2c), lower SG&A spend (+8c) and higher non-op income (+2c) were partially offset by higher R&D (-2c) and a higher tax rate (-3c) to deliver a 7c beat to our EPS estimate. We continue to view the Claris deal as a positive, and expect continued solid operating performance, backed up with patient and prudent strategic investment. We remain Neutral on BAX." (2/2/2017)
  • 3. Evercore ISI analysts commented, "BAX reported a solid finish to the year, beating consensus EPS estimates by double digits and initiating above ST EPS guidance. There were several highlights in the 4Q print, both on the topline and operating metrics that made us incrementally more positive on our 'turnaround + long term EPS power underappreciated by Street' thesis. From a revenue perspective, Renal came in above, and management highlighted continued strong adoption of AMIA PD with patient volumes doubling past few Qs (AMIA will be a key long term driver, and these trends bode well). While management guided to 3-4% growth for Renal in FY17, we think the low end of the guidance seems conservative given strength in underlying business + AMIA uptake. Within Fluid Systems, yet another strong high single digit showing highlighted the strength of Sigma Spectrum pump uptake. We found it interesting that guidance assumes 'flattening of Sigma pump in 2017', which we think is a conservative assumption (competitor BDX still expects pump share gains in FY17). Overall, the constant currency growth of ~2% seems conservative, with potential upside in the event of lack of competitive entrants for cyclo business. On the margin front, while FY17 OM of ~15% seems optically below the ~15.7% seen in 2H'16 levels (but equates to an expansion of ~150 bps over FY16), we note that it contemplates about 150 bps of headwinds related to cyclo competition, Fx & TSA rolling off. As such, the ~15% OM guidance seems prudent to us, with possible upside tied to lack of competitive cyclo entrants. Finally, the EPS guide of $2.10-2.18 does not assume any share repo and no contribution from Claris. In light of the impressive free cash increase (FY16 FCF came in 80% above original guidance; FY17 guide of >$1 Bn) and ~$1 Bn of repatriation, we see upside potential to EPS upside tied to capital deployment. All in, this was a solid print, and current levels provide a good entry point for long term holders (we note BAX repurchased $250 MM worth of shares at an avg. of $47.50 in 4Q, which is around current trading levels)." (2/1/2017)

Who are some of Baxter International's key competitors?

Who are Baxter International's key executives?

Baxter International's management team includes the folowing people:

  • Jose E. Almeida, Chairman of the Board, President, Chief Executive Officer
  • James K. Saccaro, Corporate Vice President and Chief Financial Officer
  • Giuseppe Accogli, Senior Vice President, President - Global Businesses
  • Brik V. Eyre, Senior Vice President, President - Americas
  • Marcus Schabacker M.D. Ph.D., Chief Scientific Officer, Corporate Vice President
  • Scott Pleau, Corporate Vice President - Operations
  • Sean Martin, Corporate Vice President, General Counsel
  • Jeanne K. Mason Ph.D., Corporate Vice President - Human Resources
  • Paul Vibert, Corporate Vice President, President - International
  • Thomas T. Stallkamp, Lead Independent Director

Who owns Baxter International stock?

Baxter International's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Nationwide Fund Advisors (0.15%), Bartlett & Co. LLC (0.10%), PGGM Investments (0.08%), Meeder Asset Management Inc. (0.02%), Mutual of America Capital Management LLC (0.01%) and Oakbrook Investments LLC (0.01%). Company insiders that own Baxter International stock include Albert P L Stroucken, Brik V Eyre, Carole J Shapazian, Giuseppe Accogli, James R Gavin III, John D Forsyth, Jose E Almeida, Kornelis J Storm, Peter S Hellman and Thomas T Stallkamp. View Institutional Ownership Trends for Baxter International.

Who sold Baxter International stock? Who is selling Baxter International stock?

Baxter International's stock was sold by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors, Quantitative Systematic Strategies LLC, Meeder Asset Management Inc. and Bartlett & Co. LLC. Company insiders that have sold Baxter International stock in the last year include Albert P L Stroucken, Brik V Eyre, Carole J Shapazian, Giuseppe Accogli, James R Gavin III, John D Forsyth, Peter S Hellman and Thomas T Stallkamp. View Insider Buying and Selling for Baxter International.

Who bought Baxter International stock? Who is buying Baxter International stock?

Baxter International's stock was acquired by a variety of institutional investors in the last quarter, including Oxbow Advisors LLC, PGGM Investments, Oakbrook Investments LLC, Balasa Dinverno & Foltz LLC, Park National Corp OH and Mutual of America Capital Management LLC. View Insider Buying and Selling for Baxter International.

How do I buy Baxter International stock?

Shares of Baxter International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Baxter International's stock price today?

One share of Baxter International stock can currently be purchased for approximately $64.12.


MarketBeat Community Rating for Baxter International (NYSE BAX)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  445 (Vote Outperform)
Underperform Votes:  383 (Vote Underperform)
Total Votes:  828
MarketBeat's community ratings are surveys of what our community members think about Baxter International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Baxter International (NYSE:BAX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 5 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.55)
Consensus Price Target: $65.73 (2.51% upside)
Consensus Price Target History for Baxter International (NYSE:BAX)
Price Target History for Baxter International (NYSE:BAX)
Analysts' Ratings History for Baxter International (NYSE:BAX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/15/2017Cowen and CompanySet Price TargetHold$68.00N/AView Rating Details
10/13/2017BMO Capital MarketsReiterated RatingBuy$70.00N/AView Rating Details
10/3/2017Royal Bank Of CanadaReiterated RatingHold$60.00LowView Rating Details
8/17/2017Citigroup Inc.Initiated CoverageNeutral -> Neutral$63.00LowView Rating Details
7/27/2017Leerink SwannReiterated RatingOutperform$67.00 -> $75.00LowView Rating Details
7/27/2017Barclays PLCBoost Price TargetOverweight$64.00 -> $70.00LowView Rating Details
7/26/2017Cantor FitzgeraldSet Price TargetBuy$70.00MediumView Rating Details
7/25/2017Morgan StanleyReiterated RatingUnderweight$52.00 -> $55.00MediumView Rating Details
5/31/2017Stifel NicolausBoost Price TargetHold$58.00 -> $61.00LowView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Reiterated RatingConviction-Buy$71.00HighView Rating Details
4/29/2017Evercore ISIReiterated RatingOutperform$57.00 -> $60.00LowView Rating Details
10/13/2016Wells Fargo & CompanyInitiated CoverageOutperformN/AView Rating Details
8/15/2016ArgusReiterated RatingHoldN/AView Rating Details
7/27/2016J P Morgan Chase & CoBoost Price TargetNeutral$45.00 -> $48.00N/AView Rating Details
6/13/2016Piper Jaffray CompaniesReiterated RatingOverweight$60.00N/AView Rating Details
5/10/2016Credit Suisse GroupReiterated RatingHoldN/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Baxter International (NYSE:BAX)
Earnings by Quarter for Baxter International (NYSE:BAX)
Earnings History by Quarter for Baxter International (NYSE BAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$0.59N/AView Earnings Details
7/26/2017Q2 2017$0.57$0.63$2.59 billion$2.61 billionViewN/AView Earnings Details
4/26/2017Q1 2017$0.51$0.58$2.43 billion$2.48 billionViewN/AView Earnings Details
2/1/2017Q416$0.52$0.57$2.65 billion$2.65 billionViewListenView Earnings Details
10/25/2016Q316$0.45$0.56$2.67 billion$2.56 billionViewListenView Earnings Details
7/26/2016Q216$0.40$0.46$2.51 billion$2.60 billionViewListenView Earnings Details
4/26/2016Q116$0.29$0.36$2.35 billion$2.40 billionViewListenView Earnings Details
2/2/2016Q415$0.32$0.43$2.55 billion$2.60 billionViewListenView Earnings Details
10/27/2015Q315$0.29$0.41$2.46 billion$2.49 billionViewListenView Earnings Details
7/29/2015Q215$0.94$1.00$2.40 billion$3.90 billionViewListenView Earnings Details
4/23/2015Q115$0.88$1.00$3.70 billion$3.76 billionViewListenView Earnings Details
1/29/2015Q414$1.31$1.34$4.37 billion$4.47 billionViewListenView Earnings Details
10/16/2014Q314$1.31$1.31$4.21 billion$4.20 billionViewListenView Earnings Details
7/17/2014Q214$1.21$1.26$4.12 billion$4.30 billionViewListenView Earnings Details
4/17/2014Q114$1.10$1.19$3.88 billion$3.95 billionViewListenView Earnings Details
1/23/2014Q413$1.25$1.26$4.25 billion$4.40 billionViewListenView Earnings Details
10/17/2013Q313$1.19$1.19$3.82 billion$3.80 billionViewListenView Earnings Details
7/18/2013Q2 2013$1.13$1.16$3.70 billion$3.67 billionViewListenView Earnings Details
4/18/2013Q1 2013$1.04$1.05$3.49 billion$3.45 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.26$1.26$3.72 billion$3.75 billionViewListenView Earnings Details
10/18/2012$1.14$1.14ViewN/AView Earnings Details
7/19/2012$1.11$1.12ViewN/AView Earnings Details
4/19/2012$1.00$1.01ViewN/AView Earnings Details
1/26/2012$1.17$1.17ViewN/AView Earnings Details
10/20/2011$1.08$1.09ViewN/AView Earnings Details
7/21/2011$1.02$1.07ViewN/AView Earnings Details
4/21/2011$0.93$0.98ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Baxter International (NYSE:BAX)
2017 EPS Consensus Estimate: $2.24
2018 EPS Consensus Estimate: $2.62
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.50$0.51$0.51
Q2 20172$0.55$0.56$0.56
Q3 20172$0.59$0.59$0.59
Q4 20172$0.57$0.60$0.59
Q1 20182$0.61$0.63$0.62
Q2 20182$0.65$0.65$0.65
Q3 20182$0.65$0.66$0.66
Q4 20182$0.69$0.70$0.70
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Baxter International (NYSE:BAX)
Most Recent Dividend:10/2/2017
Annual Dividend:$0.64
Dividend Yield:1.00%
Dividend Growth:-36.10% (3 Year Average)
Payout Ratio:38.79% (Trailing 12 Months of Earnings)
26.78% (Based on This Year's Estimates)
23.97% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Baxter International (NYSE:BAX)

Dividend History by Quarter for Baxter International (NYSE BAX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/18/2017quarterly$0.161.03%8/30/20179/1/201710/2/2017
5/2/2017quarterly$0.161.14%5/31/20176/2/20177/3/2017
2/21/2017quarterly$0.131.04%3/1/20173/3/20174/3/2017
11/8/2016quarterly$0.131.12%11/30/201612/2/20161/3/2017
7/19/2016quarterly$0.131.11%8/31/20169/2/201610/3/2016
5/3/2016quarterly$0.131.15%6/1/20166/3/20167/1/2016
2/16/2016quarterly$0.121.23%3/2/20163/4/20164/1/2016
11/11/2015quarterly$0.121.21%12/2/201512/4/20151/4/2016
7/29/2015quarterly$0.121.15%9/2/20159/4/201510/1/2015
5/5/2015quarterly$0.523.02%5/28/20156/1/20157/1/2015
2/17/2015quarterly$0.523.04%3/9/20153/11/20154/1/2015
11/11/2014quarterly$0.522.92%12/3/201412/5/20141/2/2015
7/22/2014quarterly$0.522.71%9/3/20149/5/201410/1/2014
5/5/2014quarterly$0.522.81%6/4/20146/6/20147/1/2014
2/18/2014quarterly$0.492.84%3/5/20143/7/20144/1/2014
11/12/2013quarterly$0.492.95%12/4/201312/6/20131/3/2014
7/23/2013quarterly$0.492.66%9/4/20139/6/201310/1/2013
5/6/2013quarterly$0.492.86%6/5/20136/7/20137/1/2013
2/19/2013quarterly$0.452.67%3/6/20133/8/20134/1/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Baxter International (NYSE:BAX)
Insider Ownership Percentage: 0.05%
Institutional Ownership Percentage: 83.60%
Insider Trades by Quarter for Baxter International (NYSE:BAX)
Institutional Ownership by Quarter for Baxter International (NYSE:BAX)
Insider Trades by Quarter for Baxter International (NYSE:BAX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/5/2017Thomas T StallkampDirectorSell8,920$62.28$555,537.60View SEC Filing  
8/25/2017John D ForsythDirectorSell9,440$61.76$583,014.40View SEC Filing  
8/24/2017Carole J ShapazianDirectorSell4,020$61.61$247,672.20View SEC Filing  
8/17/2017Giuseppe AccogliSVPSell12,670$60.96$772,363.20View SEC Filing  
5/23/2017Carole J ShapazianDirectorSell2,618$57.92$151,634.56View SEC Filing  
5/9/2017Carole J ShapazianDirectorSell3,760$55.89$210,146.40View SEC Filing  
5/8/2017Brik V EyreSVPSell130,732$55.69$7,280,465.08View SEC Filing  
4/10/2017Albert P L StrouckenDirectorSell4,280$52.80$225,984.00View SEC Filing  
3/29/2017James R Gavin IIIDirectorSell4,280$51.72$221,361.60View SEC Filing  
2/22/2017Peter S HellmanDirectorSell4,280$49.81$213,186.80View SEC Filing  
2/8/2017John D ForsythDirectorSell4,280$48.35$206,938.00View SEC Filing  
5/23/2016Jose E AlmeidaCEOBuy11,691$42.75$499,790.25View SEC Filing  
5/2/2016John D ForsythDirectorSell1,887$44.38$83,745.06View SEC Filing  
4/4/2016John D ForsythDirectorSell1,887$41.75$78,782.25View SEC Filing  
3/14/2016James R Gavin IIIDirectorSell5,660$40.34$228,324.40View SEC Filing  
2/17/2016Peter S. HellmanDirectorSell5,660$38.35$217,061.00View SEC Filing  
2/11/2016Kornelis J. StormDirectorSell5,660$35.98$203,646.80View SEC Filing  
5/22/2015Carole J ShapazianDirectorSell1,533$67.68$103,753.44View SEC Filing  
4/27/2015James R Gavin IIIDirectorSell4,830$71.06$343,219.80View SEC Filing  
7/25/2014Carole J ShapazianDirectorSell1,645$76.98$126,632.10View SEC Filing  
7/24/2014Thomas T StallkampDirectorSell8,300$76.82$637,606.00View SEC Filing  
7/9/2014Ludwig HantsonVPSell24,693$76.00$1,876,668.00View SEC Filing  
5/2/2014Carole ShapazianDirectorSell5,680$75.28$427,590.40View SEC Filing  
4/23/2014Kees StormDirectorSell5,760$72.45$417,312.00View SEC Filing  
4/21/2014Blake DevittDirectorSell4,334$73.12$316,902.08View SEC Filing  
3/27/2014Sebastian BufalinoVPSell21,600$75.10$1,622,160.00View SEC Filing  
9/12/2013Carole ShapazianDirectorSell1,941$71.58$138,936.78View SEC Filing  
8/1/2013Robert L Parkinson JrCEOSell725,750$73.33$53,219,247.50View SEC Filing  
7/26/2013David P ScharfVPSell55,438$73.79$4,090,770.02View SEC Filing  
7/25/2013James R Gavin IIIDirectorSell5,760$72.82$419,443.20View SEC Filing  
7/24/2013Carole J ShapazianDirectorSell4,320$73.58$317,865.60View SEC Filing  
7/22/2013Robert J HombachCFOSell47,452$73.95$3,509,075.40View SEC Filing  
7/16/2013Phillip L BatchelorVPSell5,850$73.00$427,050.00View SEC Filing  
5/22/2013Blake E DevittDirectorSell1,000$72.34$72,340.00View SEC Filing  
5/20/2013Sebastian J BufalinoVPSell24,000$73.75$1,770,000.00View SEC Filing  
5/17/2013Robert M DavisVPSell130,800$73.00$9,548,400.00View SEC Filing  
9/13/2012Michael J BaughmanVPSell11,500$61.00$701,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Baxter International (NYSE:BAX)
Latest Headlines for Baxter International (NYSE:BAX)
Source:
Loading headlines, please wait.

Social

Chart

Baxter International (BAX) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.